avonex fda approval

http://yourlife.usatoday.com/health/story/2012-02-28/Biogen-wins-FDA-approval-for-user-friendly-MS-drug/53287654/1 WASHINGTON (AP) – Drugmaker Biogen Idec said Tuesday that it received U.S. approval for an easier-to-use form of its multiple sclerosis injection Avonex.

s oral, Tecfidera aka BG-12, is slated for US FDA approval later this month. This new dosing for Avonex may be an effort to cut down on MS Market cannibalism as people shift from Biogen's Avonex to BG-12.

First is some good news for Avonex and Rebif users. It looks like Biogen-Idec is going to be seeking marketing approval for monthly dosing later this year. http://www.medpagetoday.com/Neurology/MultipleSclerosis/36993?utm_source=share&utm_medium=mobile&utm_campaign=medpage%2Biphone%20app Second is kind of a double edged sword. The FDA has approved over the counter sale of Oxytrol, a drug aimed at overactive bladder. They have approved it for sale to women bu not men.

Neurologist do not like to put you in [the PPMS category] because there are no FDA approved treatments for PPMS. Insurance companies do not have to pay for DMDs since they are not FDA approved." ~ "PPMS - how were you diagnosed?" http://www.medhelp.org/posts/Multiple-Sclerosis/PPMS---how-were-you-diagnosed/show/1235216 This is a good point, which I did not realize.

The FDA must approve or disapprove of telaprevir on or before May 23 of this year. How long it will take to get on the drug formularies is something we do not know yet.

Plegridy, Biogen IDEC's new version of Avonex, has been delayed by the FDA. They have extended the review period without asking for additional studies. Plegridy is Avonex on a less frequent dosing schedule. http://www.reuters.

Hi everyone, I mentioned in a thread with Julie, that Copaxone has been approved by the FDA to use in people with Clinically Isolated Syndrome. She was very interested and I posted the links there. But in case you don't see that post, I thought it would be good to start a new discussion here. This news was released by TEVA, the mfg. of Copaxone, in early March. http://www.medicalnewstoday.com/articles/141213.

I was offered to apply for the study, but I am going to wait for the approval from the FDA.

The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Approval of a drug based on such endpoints is given on the condition that post marketing clinical trials verify the anticipated clinical benefit. The FDA bases its decision on whether to accept the proposed surrogate endpoint on the scientific support for thatendpoint.

You can thank our FDA for this delay. Here is an example of how their drug approval process kills thousands of people each year! http://www.lef.org/magazine/mag2010/nov2010_FDA-Delay-of-One-Drug-Causes-Lost-Life-Years_01.

shutdown did not affect the timeline for approval. The PDUFA decision date for sofosbuvir is December 8 or 9 depending on where you look. The overall tone of this document is very encouraging for a swift approval. As a genotype 2 hoping for the all oral treatment ASAP this is very good news. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371877.pdf?

I know there are a few clinical trials going on right now for a pill form. Are there any nearing FDA approval?? And if so, when might we expect them to be available to the public?

ve been following BG12 and the majority of the mentions of its efficacy and forward path in the FDA approval process does seem to come from the financial advisers who rate stocks as to whether investors should buy, hold or sell. Right now they are all saying either buy or hold with Biogen Idec, because of the promise that BG12 will make lots of money. There may be some new news on BG12 in the ECTRIMS video links I just posted. That would give the medical perspective.

Each drug trial and treatment requires an approval from the FDA, to the best of my knowledge. In that regard, the FDA so far as Vertex may approval a plan for treating naives, a separate plan for treating past TX failures, and I assume there is one for co-infected (HCV &HIV) as well. Right now there is a current trial for BID dosing, but approval will be based on 3X daily and at some point twice daily may see an additional application.

Vertex has begun the application process for approval with the fda. The process should be completed by the end of this year with approval coming shortly after that. The results are promising and I believe the fda is going to put it on the fast track for approval. My doctor told me 6 months ago it will be probably be ready by the end of 2010. Like pcds says though, there is no way to know for sure. It may be sometime in 2011 before it is available. Hang in there!

While you can get your insurance companies to approve the treatment it still has not been approved by the FDA for ovca and my guess is since the fda has pulled their approval for breast cancer, it may be unlikely approved for ovca. I just finished cycle 4 of Avastin and am considering a change to another treatment option. I have had dibilitating headaches from Avastin. As well, I feel like my body and mind are racing....very anxious.

all the trial patients), and review all of the Safety Data so that they could resubmit Tysabri to the FDA for approval once again (Tysabri is only the second drug to be reapproved by the FDA). I was one of the MS patients that spoke before the FDA AC (via videotape) in March 2006 in an effort to bring Tysabri back to the market. I'm so very grateful that we all succeeded!

Because of my persistence, I received three phone calls from the FDA today. I'm going to now present you with the clarity of what's about to happen with the "Rolling NDA" (New Drug Application) from Vertex and other pharmaceutical companies. A Rolling NDA is an application to have the FDA put this drug on a “Priority Approval” as opposed to a “Standard Approval”. Here's the difference.

FDA Advisory Committee Unanimously Recommends Approval of Novartis Investigational Treatment FTY720 to Treat Relapsing Remitting MS -- Committee voted in favor of approval of FTY720 (fingolimod [now Gilenia]), as treatment in relapsing remitting multiple sclerosis, affirming the drugs positive benefit/risk profile -- FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing remitting MS -- Committee reco

Update. The medication was FDA approved recently and will be available next year. http://www.medscape.com/viewarticle/731619 " FDA Approves Once-Daily Lurasidone for Schizophrenia Yael Waknine October 29, 2010 — The US Food and Drug Administration (FDA) has approved the atypical antipsychotic lurasidone (Latuda tablets; Sunovion Pharmaceuticals Inc) for the once-daily treatment of patients with schizophrenia...

Avonex fda approval

Common Questions and Answers about Avonex fda approval

avonex